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Filaggrin is an intermediate filament associated protein
that aids the packing of keratin filaments during ter-
minal differentiation of keratinocytes. Premature
aggregation of keratin filaments is prevented by filag-
grin expression as the inactive precursor, profilaggrin,
which is localized in keratohyalin granules in vivo.
Profilaggrin is phosphorylated and contains multiple
filaggrin repeats separated by a hydrophobic linker
peptide. We have previously shown that filaggrin con-
structs containing the linker, when transiently trans-
fected into epithelial cells, lead to expression of a
protein that resembles keratohyalin (Dale et al, J Invest
Dermatol 108:179–187, 1997). To characterize further
the region(s) of the linker and/or filaggrin that are
necessary for granule formation, we generated several
mutant constructs from Flag–FG-1, and generated
fusions of filaggrin with green fluorescent protein. We
also subjected profilaggrin to protein phosphatase 2A
treatment and measured its subsequent solubility. We
found that granular morphology is not dependent on
Keratinization is a term used to describe both thejourney and biochemical changes of a keratinocyteas it migrates from the basal proliferative layer to therigid stratum corneum. Keratinization must be acontinuous, orderly, and life-long process to assure the
organism of an essential barrier between itself and the environment.
When a component of the process is missing or malfunctioning,
epidermal disease ensues (Compton et al, 1992; Dale et al, 1992;
Epstein, 1992; Fuchs, 1992). The most dramatic and abrupt change
of keratinization occurs at the granular to stratum corneum transition
(Odland, 1991). Here, the keratinocyte must transform itself
from a three-dimensional cell complete with active, functioning,
intracellular organelles to a flattened, two-dimensional rigid sac of
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the linker or conserved phosphorylation sites, nor is
solubility affected by protein phosphatase 2A treat-
ment. Granule morphology was abrogated only in a
truncated construct, which still contains the linker. A
construct consisting of 16 amino acids of filaggrin
fused to green fluorescent protein led to rounded and
bizarrely shaped transfected cells with compact keratin
filaments, suggesting that very little filaggrin sequence
is required for keratin filament interaction. Radio-
labeled filaggrin–green fluorescent protein constructs
specifically bound keratin in overlay assays confirming
that the observed cytoskeletal collapse is due to filag-
grin–keratin interaction. Our findings indicate that
profilaggrin must be extensively processed before it
loses both its granule forming ability as well as its
insolubility, suggesting that granule formation in vivo
correlates with insolubility in vitro. Further, filaggrin
retains its ability to bind keratin as it is degraded to
smaller peptides. Key words: filaggrin/green fluorescent
protein fusion protein/keratinization/mutagenesis. J Invest
Dermatol 112:843–852, 1999
interlocking keratin bundles. This process is rapid, occurring within
one cell layer, and presumably tightly controlled.
One identifiable biochemical event at the transition from granular
to cornified cell is the conversion of profilaggrin to filaggrin.
Filaggrin is a hydrophilic, cationic protein that aids aggregation
and subsequent disulfide bonding of keratin filaments (Dale et al,
1978). Profilaggrin is the main component of the abundant,
basophilic keratohyalin granules from which the granular layer of
the epidermis derives its name. Profilaggrin is a high molecular
weight (.400 kDa), phosphorylated protein composed of tandem
repeats of filaggrin monomers joined by small linker peptides
(Lonsdale-Eccles et al, 1984; Haydock and Dale, 1986, 1990;
McKinley-Grant et al, 1989). During the transition from granular
cell to flattened squame, conversion of profilaggrin to monomeric
filaggrin occurs by site-specific proteolysis and dephosphorylation
(Haugen-Scofield et al, 1988; Resing et al, 1984, 1989; Kam et al,
1993). The events at the granular to stratum corneum transition
must coordinate with profilaggrin processing to filaggrin to prevent
premature aggregation of the intermediate filament network. There
exist a number of disorders of human epidermis in which the
expression and/or processing of profilaggrin to filaggrin is abnormal
(reviewed in Dale et al, 1990), strongly implicating the importance
of timely processing of profilaggrin to filaggrin in normal epidermal
homeostasis.
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Figure 1. The Flag–FG-1 construct
(parental construct) and the four
constructs generated from Flag–FG-1.
The Flag–1/2Fg construct includes the linker
sequence, but terminates immediately after
FLY. The Flag–FLY to SRH construct
changes the aromatic FLY tripeptide of the
linker to SRH, a common tripeptide repeat
found in mature filaggrin. The Flag-TS to
AA and the Flag-S3 to A3 constructs change
conserved phosphorylation sites, which
correspond to P1 and P23, respectively
(Resing et al, 1995a) to alanines. The parental
construct was prepared by cloning from the
human profilaggrin gene which contains 11
filaggrin units like FG-1. The arrow indicates
the start of the amino terminus of mature
filaggrin which contains 126 amino acids
plus the 189 amino acids encoded by the
following repeat.
Expression of human filaggrin constructs containing the linker
in COS-7 and rat epidermal keratinocytes (REK) leads to granule
formation reminiscent of keratohyalin granules, whereas no granules
are seen when constructs that do not contain linker are expressed
in these same cell types (Dale et al, 1997). The difference between
constructs that lead to granule formation and those that do not is
the inclusion of a linker peptide consisting of 10 amino acids,
RSGRSGSFLY. The actual length of the linker in vivo is not
known, but has been shown to be between three and 15 amino
acids in length (McKinley-Grant et al, 1989; Gan et al, 1991;
Thulin and Walsh, 1995), with the aromatic FLY tripeptide as the
minimum three. The aromatic nature of FLY is in sharp contrast
to the markedly cationic composition of the filaggrin repeat. The
difference in the composition of the linker and filaggrin sequences
suggested that the linker may have a discrete function; perhaps
playing a part in granule formation.
The aims of our studies were (i) to clarify the region(s) of
filaggrin that are necessary for granule formation, and (ii) to ascertain
if granule formation in vivo correlates with the insolubility of
profilaggrin in vitro. Considering what is known about profilaggrin
processing in conjunction with the findings from the differential
morphology of transiently expressed proteins, we developed three
hypotheses to accomplish the first aim. These hypotheses were
based on the potential function of the aromatic linker peptide by
itself, the linker in combination with specific phosphorylation sites,
and the linker in conjunction with filaggrin sequences. We tested
these hypotheses by generating specific mutations in Flag–FG-1
and by generating fusion proteins with portions of filaggrin and
green fluorescent protein (GFP) followed by transiently expressing
the new constructs in COS-7 cells and REK.
The second aim of our studies was to correlate insolubility and
granule formation of profilaggrin. It is known that profilaggrin
undergoes both specific proteolysis and dephosphorylation during
its conversion to filaggrin. Profilaggrin has previously been shown
to become partially, but not completely, soluble with profilaggrin
endoproteinase (PEP1) digestion (Resing et al, 1995b). To add to the
proteolysis data, we examined the effect of phosphatase treatment on
the solubility of profilaggrin. We then compared the morphology
of specifically mutated granule-forming constructs with the corres-
ponding effects of proteolysis or phosphatase treatment on solubility.
Our results show that profilaggrin granule formation requires
the linker sequence in the context of the N-terminus of a filaggrin
repeat. Granule formation in situ is enhanced in larger constructs
and is not dependent on phosphorylation, consistent with the
insolubility of the phosphatase-treated protein in vitro. Further, the
linker peptide of profilaggrin is not sufficient to impart a granular
morphology to an unrelated protein, GFP. Even small filaggrin-
like sequences, when fused with GFP, however, are able to cause
altered cell shape and cytoskeletal collapse. Radiolabeled filaggrin–
GFP fusion proteins are able to bind specifically to keratin in an
in vitro overlay assay showing that the observed cytoskeletal collapse
is due to the keratin-binding ability of the transfected constructs.
MATERIALS AND METHODS
Preparation of filaggrin and GFP constructs The human filaggrin
constructs, FG-L and FG 1 L, were prepared using the polymerase chain
reaction. Flag–FG-1 and Flag–FG5 were generated by cloning single
human filaggrin units into a modified form of pcDNA3 that contains an
N-terminal Flag sequence (Dale et al, 1997). Three different mammalian
expression vectors were utilized, two containing the immediate early CMV
promoter (pcDNA3 and pCR3.1, both Invitrogen, Carlsbad, CA) and one
containing the involucrin promoter (Inv (H3700-pL2), gift of Dr. J. Carroll,
Genetics Institute, Andover (MA).
Construction of mutated profilaggrin constructs The Flag–1/2Fg construct was
generated via polymerase chain reaction (PCR) using the oligonucleotides:
59-CCCGGTACCATGGACTACAAGGACGACGAT-39 (upstream) and
59-CCCCTCGAGGTAGAGGAAAGACCCTGAACG-39 (downstream),
and the Flag–FG-1 construct as template (Dale et al, 1997). The oligonucleo-
tides contain KpnI and XhoI restriction sites (underlined, upstream and
downstream oligonucleotides, respectively) for cloning. PCR was per-
formed for 30 cycles of 1 min at 94°C, 1 min at 60°C, and 1 min at 72°C
in an AmplitronII Thermolyne thermocycler (Barnstead-Thermolyne,
Dubuque, IA). The PCR product (600 base pairs) was gel purified, digested
with KpnI and XhoI, and cloned into pcDNA3. The mutated Flag–FLY
to SRH, Flag-TS to AA, Flag-S3 to A3, and Inv-FLY to SRH constructs
were generated via site-directed mutagenesis using double-stranded DNA
as template (Braman et al, 1996). The Flag–FLY to SRH, Flag-TS to AA,
and the Flag-S3 to A3 mutations were generated from Flag–FG-1 (Fig 1).
The Inv-FLY to SRH mutation was generated from Inv-FG 1 L. The
complementary oligonucleotides used for the Flag–FLY to SRH and the
Inv-FLY to SRH constructs were as follows: PGGACGTTCAGGGT-
CTTCCCGCCACCAGGTGAGCACTC (sense) and PGAGTGCT-
CACCTGGTGGCGGGAAGACCCTGAACGTCC (anti-sense). The
complementary oligonucleotides used to generate the Flag-TS to AA
construct were as follows: PCTACCAGGTGAGCGCTCATGAACAGG-
CTGAGTCTGCCCATGG (sense) and PCCATGGGCAGACTCAGC-
CTGTTCATGAGCGCTCACCTGGTAG (anti-sense). The comple-
mentary oligonucleotides used to generate the Flag-S3 to A3 construct
were as follows: PGCCACACCACATGCCCAGGGAAGGGCTGATG-
CCGCCCGTGGGCAG (sense) and PCTGCCCACGGGCGGCATCA-
GCCCTTCCCTGGGCATGTGGTGTGGC (anti-sense). Underlined
bases represent differences from the parental construct. The mutagenic
reaction contained (in 50 µl) 2 µg dsDNA template, 125 ng each of sense
and anti-sense oligonucleotides, 0.25 mM each dNTP, and 2.5 U Pfu
polymerase (Stratagene, La Jolla, CA). The mutagenic reaction was per-
formed in an AmplitronII Thermolyne thermocycler as follows: 1 cycle of
94°C for 4 min, 50°C for 2 min, and 72°C for 2 min. This cycle was
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followed by 16 cycles of 95°C for 30 s, 55°C for 1 min, and 69°C for
13.5 min. After the amplification, 1 µl of DpnI (New England Biolabs,
Beverly, MA) was added directly to the reaction, and incubated at 37°C
for 1 h to digest the parental plasmid.
Construction of GFP plasmid and fusion proteins To clone GFP in an
expression vector from which we could generate fusion proteins, a PCR-
based approach was used. PCR was performed using the oligonucleotides:
59-CCCACCATGAGATCTAGCAAGGGCGAGGAACTGTTCACT-
GGC-39 (upstream) and 59-CCCGCGGCCGCTCACTTGTACAGCT-
CGTCCATGCCATGT-39 (downstream) and pGreen Lantern as a template
(Gibco/BRL, Grand Island, NY). The upstream oligonucleotide contains
a BglII restriction site (underlined) for cloning and an artificial translation
initiation codon (italicized). PCR was performed for 30 cycles of 1 min
at 94°C, 1 min at 55°C, and 1 min at 72°C in an AmplitronII Thermolyne
thermocycler. The PCR product (600 base pairs) was gel purified and
cloned into pCR3.1, a eukaryotic TA cloning and expression vector
(Invitrogen, Carlsbad, CA). To construct the Linker–GFP (L–GFP) and
the Linker6Fg–GFP (L6Fg–GFP) fusion constructs, the appropriate oligo-
nucleotides were annealed, digested with the appropriate restriction
enzymes, and then ligated into pCR3.1 containing the cloned GFP product,
pCR3.1–GFP. The oligonucleotides used to generate the Linker–GFP
clone were as follows: 59-CCCAAGCTTACCATGAGGTCTGGAC-
GTTCAGGGTCTTTCCTCTACAGATCTCCC-39 (sense) and 59-
GGGAGATCTGTAGAGGAAAGACCCTGAACGTCCAGACCTCAT-
GGTAAGCTTGGG-39 (anti-sense). The oligonucleotides used to generate
the Linker6FG–GFP clone were as follows: 59-CCCAAGCTTACCATG-
AGGTCTGGACGTTCAGGGTCTTTCCTCTACCAGGTGAGCAC-
TCATGAAAGATCTCCC-39 (sense) and 59-GGGAGATCTTTCATGA-
GTGCTCACCTGGTAGAGGAAAGACCCTGAACGTGGAGACCT-
CATGGTAAGCTTGGG-39 (anti-sense). HindIII and BglII restriction
sites used for cloning are underlined and artificial translation initiation
codons are italicized. Flag–FG1–GFP was generated by digesting Flag–
FG-1 with KpnI and BglII, and cloning directly into pCR3.1–GFP. A
KpnI/BglII digest of the Flag–FG-1 construct maintains the full length
Flag–FG-1 insert with the appropriate ATG start site and stays in the
correct reading frame with GFP.
Plasmid DNA was prepared by alkaline lysis and purified using Qiagen
500 columns as directed by the manufacturer (Qiagen, Chatsworth, CA).
The sequences of all mutant constructs and GFP fusion products were
verified by dye terminator cycle sequencing (Perkin Elmer, Foster City, CA).
Cell culture and transfection procedure COS-7 African Green
monkey kidney cells were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum and were passaged weekly.
REK, a generous gift from Dr. Howard Baden (Massachusetts General
Hospital, Boston, MA) were grown as previously described (Baden and
Kubilus, 1983; Haydock et al, 1993). All cell lines were tested to exclude
the possibility of Mycoplasma contamination.
COS-7 cells and REK were plated at 1 3 104 cells per well of a 12-
well plate on glass coverslips, or at 4 3 104 cells per 60 mm dish. At
µ60% confluence, cells were transfected with LipofectAMINE reagent
(Life Technologies, Gaithersburg, MD) as recommended by the manufac-
turer. For each transfection, 2.5 µg of plasmid DNA was mixed with 40 µg
lipid reagent and 1 ml serum-free Dulbecco’s modified Eagle’s medium,
added to the cells and incubated at 37°C for 4 h. At 4 h, an equal volume
of Dulbecco’s modified Eagle’s medium with 20% fetal bovine serum was
added directly to the culture dish and allowed to incubate overnight at
37°C. The following day, the culture medium was changed. Transfected
cells were harvested between 2 and 7 d after transfection. Transfections
were repeated multiple times.
For antibody staining, cells were washed in phosphate-buffered saline
(PBS), fixed in methanol/acetone (3:1), washed further in PBS, then stored
at 4°C until use. For GFP and fusion protein visualization, cells were washed
with PBS and either examined directly with fluorescence microscopy or
fixed with 4% paraformaldehyde for 10 min, postfixed in acetone for
10 min, washed further in PBS and stored at 4°C until use. For gel
electrophoresis analysis, transfected cells were extracted with 0.25 M Tris/
HCl, pH 7.8, containing 9 M urea and aprotinin (100 µg) or 0.25 M Tris/
HCl alone where indicated.
Antibodies The filaggrin monoclonal (AKH1, Dale et al, 1987) and
polyclonal antibodies (8959, Fleckman et al, 1985) were developed by our
laboratory. Monoclonal anti-keratin 14 (LL001) was a generous gift from
Dr. Irene Leigh (St. Bartholomew’s and the Royal London School of
Medicine and Dentistry, U.K.) (Purkis et al, 1990). Monoclonal antibody
to type II keratins (AE3) was a generous gift from Dr. T-T Sun (New
York University, New York, NY). Other antibodies were obtained com-
mercially and include monoclonal antibodies to keratin 8 (used for COS-7
cell studies, Sigma, St. Louis, MO), the polyclonal anti-FLAG antibody
(Santa Cruz Biotech, Santa Cruz, CA), and a polyclonal pancytokeratin
antibody (Biogenix, San Ramon, Ca). Biotin-labeled horse anti-mouse
IgG, biotin-labeled goat anti-rabbit IgG, streptavidin Texas Red, and
fluorescein isothiocyanate-labeled goat anti-rabbit IgG were all from Vector
Labs (Burlingame, CA).
Gel electrophoresis and immunoblot analysis Tris or urea/Tris
extracts of transfected cells were separated on 4–15% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) gels (Laemmli,
1970). Urea/Tris extracts of human foreskin epidermis that contain
profilaggrin and filaggrin were used as controls (Fleckman et al, 1985).
Proteins were blotted to nitrocellulose and immunoreactive proteins
visualized with the avidin–biotin method using 4-chloro-1-naphthol
(Haydock et al, 1993).
Immunofluorescence detection of expressed proteins and other
cellular constituents Indirect immunofluorescence microscopy was per-
formed on transfected cells with the primary antibody (8959 1:500,
anti-FLAG antibody 1:200), followed by the application of the proper
fluorescein-conjugated secondary antibody (fluorescein isothiocyanate goat
antirabbit IgG, 1:200). The anti-Flag antibody was used to detect expression
of exogenous protein in REK to avoid cross-reactivity of 8959 with
endogenous rat profilaggrin. For double immunofluorescence, monoclonal
antibody was applied (LL001 1:200, anti-K8 1:200), followed by secondary
biotin-labeled horse antimouse IgG (1:200) and streptavidin–Texas Red
(1:800). To obtain keratin staining in paraformaldehyde-fixed cells trans-
fected with GFP constructs, all antibody incubations were performed with
the addition of 0.01% saponin to the dilution buffer (anti-keratin 8 antibody
1:100, pankeratin antibody 1:50, biotin-labeled goat anti-rabbit or horse
anti-mouse antibody 1:200, streptavidin–Texas Red 1:800). All incubations
were for 1 h at room temperature with multiple PBS washings in between.
For DNA staining, samples were incubated in 0.001% 496-diamidino-2-
phenylindole dihydrochloride (Sigma) for 10 min then washed with PBS.
Samples were coverslipped using Vectashield mounting media to minimize
fading. Image acquisition was on either a BioRad MRC-600 laser scanning
confocal microscope equipped with a krypton/argon mixed gas laser
(Cambridge, MA) or a Nikon Microphot-SA microscope equipped with
a CCD camera (Photometrics, Tucson, AZ). Data was collected either as
a Z series (0.2 µM/step) or single 1024 images. The sequentially recorded
gray scale images were deconvoluted, pseudocolored, and merged using
the software program IPLab (Signal Analytics, Vienna, VI).
Overlay binding assays
Keratin preparation Keratins used as substrate for the overlay binding assays
were obtained from neonatal foreskin. The epidermis was separated form
the dermis by incubating in 5 mM ethylenediamine tetraacetic acid in PBS
at 50°C for 3 min. Each epidermis was homogenized in 500 µl of 9 M
urea and 50 mM Tris pH 8.0 to which a crystal of phenylmethylsulfonyl
fluoride had been added. The extracts were then loaded on to a DE52
column that had been equilibrated with the urea/Tris buffer and washed
with the same buffer. A linear gradient of 0–0.3 M NaCl was run, fractions
collected and analyzed by SDS–PAGE and stained with Coomassie Blue.
An aliquot of pooled keratin-containing fractions was dialyzed against
25 mM NaPO4 and 6 M urea containing 10 mM β-ME to remove Tris
ions which interfere with the cross-linking agent (Paladini et al, 1996).
Bis-(sulfosuccinimidyl) suberate) was added at a final concentration of
5 mM to the dialyzed keratin fraction for 1 h at room temperature to
cross-link covalently the dialyzed keratin aliquot. Monomer and cross-
linked keratin fractions were boiled in SDS–PAGE sample buffer, separated
by 5%–10% SDS–PAGE, then transferred to nitrocellulose. Multiple strips
were prepared in this manner to use as substrate for subsequent overlay assays.
Preparation of protein probes Protein probes used in the overlay assays were
prepared from 1 µg plasmid DNA using the TnT Quick Coupled
Transcription/Translation System (Promega, Madison, WI) in the presence
of L-[35S]-methionine (Redivue, Amersham Life Sciences, Arlington
Heights, IL). Unincorporated L-[35S]-methionine was removed from the
TnT reaction mix prior to further use as described (Smith and Fuchs,
1998). Equal amounts of protein were used for the overlay assays (BioRad
Protein Assay, BioRad Laboratories, Hercules, CA).
Overlay assay Nitrocellulose strips, each containing a lane of both keratin
monomers and cross-linked keratins, were washed in Tris-buffered saline/
0.1% Tween for 1 h at room temperature. Equal amounts of radiolabeled
protein were diluted in a buffer containing 50 mM Tris, pH 7.6, 75 mM
NaCl, 10 mM β-ME, 10 mM dithiothreitol, and 0.1% hexadecyl trimethyl-
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ammonium bromide (Sigma), then overlayed on to the keratin strips at
4°C for 16 h. Nitrocellulose strips were then washed with 50 mM Tris,
pH 7.6, 75 mM NaCl, and 0.05% Tween, 4 3 for 30 min each wash,
dried, and exposed to X-ray film for varying time points.
Phosphatase treatment and subsequent solubility 32P-labeled mouse
profilaggrin was prepared as follows: newborn Swiss Webster mice were
each injected subcutaneously with 20 µl labeling cocktail (35 mM HEPES,
170 mM NaCl, pH 7.2, with 180 µCi 32P-orthophosphoric acid per
mouse) and killed after 4 h. The epidermis was separated from the dermis
by heating the skin 4–6 min in PBS with 10 mM ethylenediamine
tetraacetic acid at 58°C. Each epidermis was homogenized and pooled
proteins separated as described above (keratin preparation), except that
prior to column chromatography, the supernatant was incubated at room
temperature for 40 min to allow cross-linking of keratins, which were
then pelleted by centrifugation at 12,000 3 g for 15 min. Fractions
containing the profilaggrin were pooled and desalted over p-6DG spin
columns (BioRad Laboratories) and equilibrated with the urea buffer. It
has been noted that preparation of rodent profilaggrin by extraction in
9 M urea preserves more than 95% of the profilaggrin-bound phosphate
(Resing et al, 1995a). Dephosphorylation of profilaggrin was as follows: In
each of several plastic tubes 20 µl of 1.6 mg per ml 32P-labeled mouse
profilaggrin was precipitated by adding 200 µl 10 mM MgCl2 and
incubating on ice for 10 min followed by centrifugation. After discarding
the supernatant, 50 µl of 210 mM HEPES, 0.5 mM MgCl2, 5 mM
dithiothreitol, pH 7.2, with 0.33 units per µl bovine heart protein
phosphatase 2A (PP2A) catalytic subunit (a gift from Dr. Timothy Haystead
(University of Virginia) via Dr Natalie Ahn (University of Colorado,
Boulder), prepared according to the method of Tung et al, 1984) were
added to each tube. The reaction was incubated at 37°C. To quench the
reactions and separate the free from the protein-bound 32P-phosphate,
20 µl of a 10% bovine serum albumin solution and 200 µl of 20%
trichloroacetic acid were added to each reaction tube. The tubes were
then vortexed vigorously and put on ice for 40–60 min, followed by
centrifugation for 5 min in a microcentrifuge. The supernatants were
decanted and both supernatants and pellets were counted by Cerenkov
methods. To examine the solubility of dephosphorylated profilaggrin,
mouse profilaggrin was deposited on tubes as above, following which 20 µl
of 250 mM HEPES, 5 mM dithiothreitol, pH 7.2 with 0.5 units per µl
PP2A catalytic subunit was added. Following incubation at 37°C, super-
natants were decanted and Laemmli SDS–PAGE sample buffer was added
to supernatants and pellets, which were then separated on 4%–16% gradient
SDS gels.
RESULTS
Granule formation does not require the FLY sequence of
the linker Previous results showed granule formation by filaggrin
constructs containing linker, but not with those lacking the linker
sequence. Our first hypothesis was that the aromatic FLY tripeptide
of the linker is so distinct from the surrounding charged amino
acids of filaggrin that it is a likely candidate for playing a part in
granule formation. A FLY (194–196) to SRH mutation was
constructed to test this hypothesis. SRH is a common tripeptide
repeat found in mature filaggrin. Thus, a FLY to SRH mutation
would make the Flag–FG-1 construct similar in sequence to a
mature filaggrin monomer (Fig 1), which does not form granules
in a transient transfection assay. Distinct granules, however, were
seen when the Flag–FLY to SRH mutant construct was expressed
in COS-7 cells and REK. In fact, the granules in COS-7 cells
were larger than those of the parent construct. The large granules
appear to be preferentially located in the nucleus (Fig 2b, g, verified
by step sectioning), although no known nuclear localization signal
was generated with this mutation according to standard protein
sequence analysis programs (Prosite, Bairoch, 1993). Further, the
Flag–FLY to SRH construct did not appear to cause cytoskeletal
collapse.
Granule formation does not require phosphorylation of
conserved phosphorylation sites Our second hypothesis
reasoned that conserved phosphorylation sites may have a part in
granule formation. We therefore altered two groups of phosphoryl-
ation sites in human filaggrin, one adjacent to the linker peptide
and one located downstream, that are conserved and known to be
phosphorylated in rat profilaggrin (Fig 1) (Resing et al, 1995a).
These sites were chosen based on their proximity to the linker and
hence a potential interaction with the linker (Flag-TS to AA, T201
and S205) as well as their increased susceptibility to dephosphoryl-
ation by PP2A (both Flag-TS to AA and Flag-S3 to A3, S278, S282,
S285) (C. Thulin, unpublished observation). The Flag-TS to AA
construct substitutes alanines for conserved threonine and serine
residues near the linker region, and the Flag-S3 to A3 construct
substitutes alanines for three conserved serine residues found further
in the protein. In both COS-7 cells and REK, the granules formed
by the Flag-TS to AA and the Flag-S3 to A3 proteins (Fig 2c, d,
h, i) were indistinguishable from those of the parent protein
(Fig 2e, j).
We had previously seen (Dale et al, 1997) that granule formation
using a construct with the linker at the N-terminus (either the
CMV-FG 1 L or the Inv-FG 1 L construct) is dependent on the
type of cell in which the construct is expressed, as granules were
seen in REK but not COS-7 cells. This would suggest that there
are cell-specific factors which assist in granule formation. We
therefore generated a FLY to SRH mutation in the Inv-Fg 1 L
construct for transfection into REK. This construct also yielded
granules in REK with no morphologic difference between parent
and mutated protein when expressed in REK (data not shown).
Granule formation in COS-7 cells and REK requires linker
peptide in the context of filaggrin As the first two hypotheses
tested failed to generate a construct that abrogated granule forma-
tion, we reasoned that the linker sequence works in the context
of filaggrin-specific sequences to form granules. We therefore
generated a Flag-1/2 filaggrin (Flag-1/2Fg) construct that contains
186 amino acids plus the linker sequence but is lacking 129 amino
acids of the filaggrin repeat (Fig 1). In vivo, each mature filaggrin
repeat begins immediately after FLY (Fig 1, arrow, Thulin and
Walsh, 1995). Therefore, in contrast to the Flag-FG-1 construct,
in which the linker sequence is located in the middle, the Flag-1/
2Fg construct lacks the amino terminal 129 amino acids of a mature
filaggrin monomer. Repeated transfections with this construct led
to expression of a protein that was found diffusely throughout the
cell (Fig 2a, f). Interestingly, the apparent transfection rate fell
dramatically, and the positively transfected cells demonstrated altered
cell shapes (Fig 2a, f), similar to previous observations seen
with cells transfected with constructs encoding a mature filaggrin
sequence. These results suggest that filaggrin constructs that yield
diffuse protein expression and do not form granules are able to
bind the keratin cytoskeleton, leading to cellular collapse and loss
of transfected cells from the population. Conversely, filaggrin
constructs that encode granular forms of the protein are less
detrimental on the cell, and do not collapse the keratin cytoskeleton.
The linker peptide RSGRSGSFLY, is not able to impart a
granular morphology to an unrelated protein GFP is diffusely
expressed when transiently transfected into both COS-7 cells and
REK (Fig 3b, b9). We generated a construct that consisted of the
linker sequence, RSGRSGSFLY, fused with GFP. This
L–GFP construct yielded a diffusely expressed autofluorescent
protein indistinguishable from native GFP (Fig 3c, c9). To test the
hypothesis that the linker works in conjunction with N-terminal
elements of a filaggrin repeat as suggested by our findings with
Flag–1/2Fg, we created a GFP fusion protein that contains the
linker peptide plus the first six amino acids of a filaggrin repeat,
RSGRSGSFLY-QVSTHE. This construct, L6Fg–GFP, contains
the first conserved phosphorylation site in the N-terminus of
filaggrin (underlined T). L6Fg–GFP, when expressed in both COS
cells and REK, did not yield granules (Fig 3d, d9). This construct,
however, altered the cytoskeleton, led to shape changes, and
decreased the number of positively transfected cells, analogous to
the findings seen with the filaggrin and Flag–1/2Fg constructs. To
examine the changes seen with the L6Fg–GFP construct further,
transfected cells were stained with an anti-keratin antibody (Fig 4a–
f). Cells expressing L6Fg–GFP were smaller and exhibited a
retracted cytoskeleton compared with cells expressing GFP alone.
This suggests that a peptide containing only a few filaggrin-like
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Figure 2. The Flag–1/2Fg construct
yields expression of a diffuse protein,
whereas the Flag–FLY to SRH, Flag-TS
to AA, and the Flag-S3 to A3 constructs
yield expression of a granular protein.
Cells were transfected with the indicated
contructs as described in Materials and Methods.
COS-7 cells (a–e) were stained with the
polyclonal anti-filaggrin antibody 8959 and a
monoclonal antibody against keratin 8. REK
(f–j) were stained with the polyclonal anti-
Flag antibody and a monoclonal antibody
against K14. Transfections and antibody
staining were performed multiple times. The
two-color overlays are shown. The Flag–1/
2Fg construct led to expression of a diffusely
expressed protein (a, f) with no evidence of
granule formation. Further, cells expressing
the construct exhibited a distorted and/or
contracted keratin network. The FLY to SRH
construct, the TS to AA construct, and the S3
to A3 construct led to expression of a granular
protein (b–d, g–i). The granules found with
the FLY to SRH mutation were preferentially
located in the nucleus (b, g, arrows). Nuclear
localization was verified by step sectioning.
The granules seen with the Flag-TS to AA
and the Flag-S3 to A3 were indistinguishable
from those seen with the Flag–FG-1 construct
(c–e, h–j).
residues (16 amino acids) is able to interact with keratin in a
manner like mature filaggrin.
Filaggrin and filaggrin-like peptides are able to specifically
bind keratin in an in vitro overlay assay To verify that the
observed cytoskeletal collapse seen with L6Fg–GFP construct is
due to the ability of the expressed protein to bind keratin, we
performed overlay assays using 35S-radiolabeled protein. We were
limited to performing the overlay assay using only GFP and our
GFP fusion proteins, as filaggrin contains no methionine or lysine,
and therefore cannot be labeled in a manner appropriate for
detection. Labeled GFP and GFP fusion constructs are shown in
Fig 5(A). In vivo, it is thought that filaggrin recognizes keratin dimers
or larger intermediate filaments. Therefore, we biochemically cross-
linked the epidermal keratins (Fig 5B) anticipating that filaggrin
would require keratin dimers for binding to occur. Cross-linking
under these conditions resulted in primarily dimers and trimers
(Fig 5B, lane 1) compared with the control monomers (Fig 5B,
lane 2). Similar pairs of cross-linked keratins and control monomers
were used to test binding of radiolabeled filaggrin constructs
(Fig 5C). The autoradiogram (Fig 5C) shows that filaggrin
constructs recognize both keratin monomers and cross-linked
keratins.
Using equal amounts of protein labeled under identical conditions
in the GFP domain, the L6Fg–GFP binds to keratins with the
highest affinity. Both constructs bind to monomer and cross-linked
forms of keratin, whereas Flag-FG1–GFP binds with weaker affinity.
The L–GFP protein appears to bind weakly to keratin monomers,
but not to cross-linked keratins. GFP by itself does not bind to
keratin, indicating that binding is specifically due to the filaggrin
domains. The strong binding of keratin seen with L6Fg–GFP
in vitro suggests that the cytoskeletal collapse we observed when
the protein is transiently expressed in epithelial cells is a direct
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Figure 3. GFP and filaggrin–GFP fusion
proteins expressed in COS-7 cells and
REK. COS-7 (a–e) cells and REK (a9–
e9) were transfected with GFP constructs
encoding for GFP and GFP fusion proteins
as described in Materials and Methods. Cells
were fixed at 48 h, stained with 496-
diamidino-2-phenylindole dihydrochloride,
and visualized with epifluoresence. (a, a9)
Negative autofluoresence in mock-
transfected cells. (b, b9) Expression of native
GFP. (c, c9) Expression of the L–GFP fusion
product which is indistinguishable from
native GFP. (d, d9) Expression of the L6Fg–
GFP fusion protein. These cells appear to
have altered cell shapes compared with cells
expressing native GFP or L–GFP (arrows). (e,
e9) Expression of the Flag-FG1–GFP fusion
protein. Distinct granules are seen on a diffuse
green background (arrows).
result of keratin binding. The weaker association of Flag-FG1–
GFP with keratins is consistent with the absence of cytoskeletal
collapse in transfected cells. Nevertheless, it is not surprising that
we see some specific binding to keratin in this overlay assay, as the
same protein sequence is present in this construct as in the L6Fg–
GFP construct.
To detect associations between keratin and filaggrin, we found
it necessary to perform the binding step in the presence of a
cationic detergent, hexadecyl trimethyl-ammonium bromide. In
the absence of detergent, or in the presence of a neutral detergent
(Tween) or an anionic detergent (SDS) in the overlay buffer, no
specific interaction between filaggrin and keratin was detected (data
not shown). This suggests that the interaction between filaggrin
and keratin is mediated by ionic interactions as previously proposed
(Mack et al, 1993; see Discussion).
Flag–FG-1 is both granular and diffuse As a positive control
for granule formation, we created a fusion protein with Flag–FG-1
(which forms granules) and GFP. When expressed in both cell
types, the FLAG-FG1–GFP fusion protein exhibited granules in the
nucleus and cytoplasm plus a more diffuse, nongranular expression
pattern (Fig 3e, e9). Although the filaggrin–GFP fusion constructs
were engineered with only one ATG start site, we wondered if
the combination diffuse/granular pattern seen with the Flag-FG1–
GFP fusion product represented exclusively the true full length
protein, or if the morphologic pattern reflected proteolytic cleavage
of the protein. Immunoblot analysis of lysates from a population
of transfected cells (Fig 6) showed a single band in the Flag-FG1–
GFP lane, ruling out the expression of a mixed population of
expressed GFP proteins. We previously observed that the Flag–
FG-1 construct yielded mainly a granular pattern with anti-filaggrin
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Figure 4. L6Fg–GFP expression leads to
altered cell shape. REK were transfected
with native GFP (a, b, c) or L6Fg–GFP (d, e,
f), fixed and stained with an anti-pankeratin
antibody and 496-diamidino-2-phenylindole
dihydrochloride. Cells were visualized with
epifluorescence microscopy. Autofluorescent
GFP (green; a, d), keratin staining (red; b, e),
and the three color overlays (c, f) are shown.
Compared with native GFP, expression of
L6Fg–GFP caused the cells to shrink and the
cytoskeletal network to collapse around the
nucleus as seen by pankeratin staining.
antibodies, but would often observe a more diffuse pattern of
expression along with granules when using the anti-Flag antibody
(Fig 2g, h, j). Our results with the Flag-FG1–GFP fusion protein
verify that Flag–FG-1 is expressed in both granular and diffuse forms.
Biochemical studies on the role of the linker: solubility
in vitro Within the repeating portion of profilaggrin (i.e., exclud-
ing the amino-terminal and carboxyl-terminal domains), profilag-
grin and filaggrin share similar amino acid compositions with the
exception of the aromatic linker peptides, yet exhibit markedly
different solubility profiles. Filaggrin is highly soluble in aqueous
buffers, whereas profilaggrin is insoluble in the absence of denatur-
ants such as urea or high salt concentrations. It has previously been
shown that PEP1 treatment of radiolabeled mouse profilaggrin,
which cleaves but does not remove the linker peptide, results in
partial solubilization of profilaggrin (Resing et al, 1995b). The
smallest product of PEP1 treatment, analogous to the Flag–FG-1
construct is only partially soluble, and is still phosphorylated. This
finding is consistent with the mixed granular/diffuse pattern seen
with the Flag–FG-1 construct, visualized either indirectly with the
anti-Flag antibody or directly via the Flag–FG1–GFP fusion protein.
PP2A has been shown to remove phosphate from filaggrin that
was phosphorylated in vitro with casein kinase II (Kam et al, 1993).
This phosphatase removes more than half of the radioactive
phosphate from in vivo labeled mouse profilaggrin (Fig 7a). The
phosphorylation sites of profilaggrin in human are not completely
characterized. The sites mutated in the Flag-TS to AA and the
Flag-S3 to A3 constructs, though, are conserved between known
rat phosphorylation sites (Resing et al, 1995a) and are sites of PP2A
activity. We found that profilaggrin treated with PP2A, was
indistinguishable from untreated protein in solubility assays (Fig 7b).
Although it is possible that phosphorylation sites not affected by
PP2A determine solubility (PP2A does not completely dephos-
phorylate profilaggrin), these results with PP2A and solubility
combined with the lack of morphologic change in the protein
mutated at phosphorylation sites subject to PP2A action, lead us
to conclude that PP2A dephosphorylation of profilaggrin does not
affect granule formation. It is possible there are one or more
phosphorylation sites in profilaggrin not affected by PP2A that are
involved in granule formation that we have not identified; however,
we feel this is not likely based on comparisons between human
and rodent profilaggrin.
DISCUSSION
Granule morphology and profilaggrin processing We have
previously demonstrated that multimeric filaggrin proteins yield
granules that resemble keratohyalin when transiently transfected
into COS-7 cells and REK (Dale et al, 1997). In the present study,
we demonstrate that the granule-forming ability of Flag–FG-1 is
retained when (i) a conserved, aromatic tripeptide, FLY, is mutated
to the common tripeptide motif SRH, and (ii) when conserved
phosphorylation sites are mutated to alanines, preventing phos-
phorylation. The ability of Flag–FG-1 to form granules is lost,
however, when the protein is terminated immediately after but still
retaining the FLY tripeptide. These findings indicate that the
aromatic tripeptide, FLY, is not the determinant of granule forma-
tion, nor is the phosphorylation state of the protein solely responsible
for granule formation. Granule formation can be abrogated even
in the presence of FLY, as evidenced by the Flag–1/2Fg construct.
Keeping in mind that the Flag–1/2Fg construct lacks what would
be the first 129 amino acids of a mature filaggrin repeat in vivo, it
appears that granule formation is dependent on the interaction of the
linker peptide with the amino-terminus of filaggrin. Furthermore,
linker interaction with filaggrin does not require FLY in the linker
in order to form granules, as evidenced by our findings with the
Flag–FLY to SRH and the Inv-Fly to SRH constructs.
These studies also demonstrate the successful generation of
various GFP fusion proteins with portions of filaggrin. GFP has
been fused with other proteins to examine changes in protein
distribution and function (Patino et al, 1996; Ludin and Matus,
1998), with little to no effect on the fusion partner. From these
fusion proteins, we have learned that the linker RSGRSGSFLY, is
not sufficient to impart a granular morphology to an unrelated
protein, GFP. The fact that the linker alone is unable to impart a
granular morphology to an unrelated protein is further evidence
that granule formation relies on the interaction of the linker with
filaggrin specific sequences. We have also shown that the L6Fg–
GFP construct, RSGRSGSFLY-QVSTHE–GFP, has a similar effect
on transiently transfected cells as does a full-length filaggrin con-
struct. Mack et al (1993) have shown that synthetic filaggrin-like
peptides can effectively bind intermediate filaments provided they
have the correct charge, polar distribution, and fundamental tetra-
peptide repeat (S/G-S/G-S/G/polar-S/G/basic/acidic). The 16
amino acids of the L6Fg–GFP construct partially fulfill these criteria.
The apparent transfection rate fell to less than 2% of cells when
transfecting with the L6Fg–GFP construct compared with 10–15%
of cells when transfecting with the GFP, L–GFP, or Flag FG1–GFP
constructs. Similar observations were also made when comparing the
low transfection rates (,2%) of the CMV-Fg or Inv-Fg constructs
to the transfection rates obtained with the Flag–FG-1, Flag–FG5,
or the Inv 1 L constructs (10%–15%, Dale et al, 1997). This
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Figure 5. Evidence for direct interaction between filaggrin and
epidermal keratins. (A) In vitro transcribed/translated proteins (TnT
Quick Coupled System, Promega, Madison, WI) separated by SDS–PAGE
and visualized by autoradiography. (B) Epidermal cross-linked keratins (lane
1) and keratin monomers (lane 2) separated by 5%–10% SDS–PAGE,
transferred to nitrocellulose, and blotted with an anti-keratin antibody
(AE3). Identical nitrocellulose strips were used in subsequent overlay assays.
(C) Overlay assay of epidermal keratins using 35-S-radiolabeled filaggrin–
GFP fusion constructs and controls. Equal amounts of protein were used
for incubation with each blot containing cross-linked and monomeric
keratins. Note the strong interaction between L6Fg–GFP and keratin and
the lesser interaction between Flag–FG1–GFP and keratin. L–GFP appears
to interact weekly with keratin monomers, but not with cross-linked
keratins. GFP and the negative control show no interaction with keratin.
suggests that when a protein is expressed that has the ability to
bind to intermediate filaments, normal cell function is compromised,
with loss of those cells from the population.
How do these findings relate to profilaggrin processing as found
in normal epidermal differentiation? During terminal differentiation,
profilaggrin found in keratohyalin granules is converted to filaggrin,
which is diffusely distributed and bound to keratins, via several
identifiable events. Although the signal that initiates processing is
not known, several of the enzymatic steps have been described.
Both the amino terminus and a short carboxy extension beyond
the final filaggrin repeat, are cleaved (Haydock and Dale, 1990;
Rothnagel and Steinert, 1990). The unique amino terminus of
profilaggrin with its two distinct calcium binding domains (Presland
Figure 6. Immunoblot analysis of Flag–FG1 and GFP fusion
proteins. Tris extracts of COS-7 cells were separated by 4%–15% SDS–
PAGE, transferred on to nitrocellulose and blotted with 8959 antibody.
The diffuse expression pattern seen in conjunction with granules in cells
transfected with the Flag–FG1–GFP construct is not due to degradation.
Lanes 1–5 represent Tris extracts of COS-7 cells transfected with the
following constructs: lane 1, GFP; lane 2, L–GFP; lane 3, L6Fg–GFP; lane
4, Flag–FG1–GFP; and lane 5, Flag–FG1 (without the GFP tag). The
predicted molecular weight of GFP is 24.5 kDa and the predicted molecular
weight of Flag–FG1 is 36 kDa, although this construct tends to run higher
than 36 kDa, probably due to its basic nature. The predicted molecular
weight of the Flag–FG1–GFP fusion protein is 60.5 kDa.
Figure 7. Dephosphorylation does not solubilize profilaggrin. (A)
PP2A removes over half of the phosphate from 32P-profilaggrin (see
Materials and Methods for details of experiment). Results from duplicate
experiments are shown. (B) Coomassie-stained SDS–PAGE of supernatants
(left four lanes) and precipitates (right four lanes). Note that all profilaggrin
remains in the insoluble fraction even after 60 min of PP2A digestion.
et al, 1995) undergoes specific proteolysis (Presland et al, 1997).
Further exopeptidase processing of the amino and carboxyl termini
of filaggrin may occur (Resing et al, 1993b). Specific proteolysis
occurs at the linker region (Resing et al, 1993a), and extensive
dephosphorylation by one or more phosphatases, including PP2A
occurs (Kam et al, 1993).
We conclude from these studies that profilaggrin must undergo
extensive processing before it becomes diffusely distributed within
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the cell, and that granule formation of filaggrin correlates with
little or no interaction with keratin intermediate filaments. The
requirement for extensive processing may prevent premature inter-
mediate filament collapse during terminal differentiation of the
epidermis.
Granular morphology and solubility Solubility studies of
profilaggrin demonstrate that even the smallest product of endo-
protease digestion (analogous to Flag–FG-1) is only partially soluble
(Resing et al, 1995b). Furthermore, phosphorylation appears to
have no effect on determining solubility. Does profilaggrin insolubil-
ity in vitro correspond to granule formation in vivo? Flag–FG-1,
when stained with the polyclonal anti-filaggrin antibody 8959,
appears granular (Fig 2e). Use of the anti-Flag antibody, however,
reveals a mixed granular-diffuse pattern of expression (Fig 2j). The
Flag-FG1–GFP fusion protein, which can be visualized directly,
bypassing the need for antibody, also exhibits a mixed granular-
diffuse pattern of expression (Fig 3e, e9). We attribute the difference
in staining patterns between the anti-filaggrin antibody, 8959, and
the anti-Flag antibody to differences in epitope recognition. Because
the Flag-FG1–GFP fusion protein also exhibits a mixed granular-
diffuse pattern that is not due to proteolysis (Fig 6), we conclude
that Flag–FG-1 is indeed expressed in both a granular and diffuse
form. The mixed granular/diffuse pattern of expression correlates
with the partial solubilization seen with endoprotease treatment.
Further, the fact that the proteins expressed using the Flag-TS to
AA and the Flag-S3 to A3 constructs were indistinguishable from
the parental protein, i.e., no change in granule formation, correlates
with the fact that dephosphorylation at these sites has no effect on
filaggrin solubility. In fact, the only construct in which granule
formation was not seen was Flag–1/2Fg. Harding and Scott (1983)
demonstrated that profilaggrin becomes dephosphorylated prior to
formation of filaggrin, and that filaggrin continually undergoes
degradation to free amino acids in the stratum corneum. Their
findings, taken in the context of our data on solubility, indicate
that (i) dephosphorylation does not appear to contribute to solubility
and that (ii) solubility of filaggrin may not be determined by a
single specific proteolytic event but rather by a series of proteolytic
events to shorten filaggrin to a critical ‘soluble’ length.
We conclude from these studies that profilaggrin morphology
in vivo correlates with profilaggrin solubility in vitro. We also
conclude that extensive processing of profilaggrin occurs before
the protein is found only in the diffuse form.
The results of these studies indicate that once the initiating event
has occurred in vivo, profilaggrin becomes progressively more
soluble. While limited, partial keratin filament binding occurs with
constructs that exhibit granular morphology, significant binding
does not appear until the granular morphology is abolished. Specific
keratin binding in vitro correlates directly with the degree of
cytoskeletal collapse seen in vivo. Small filaggrin-like peptides can
induce keratin filament collapse, and collapse is not prevented
when the peptide includes FLY. Granular morphology is maintained
until extensive processing of profilaggrin has occurred, and is not
dependent on FLY or conserved phosphorylation sites. Our findings
indicate that profilaggrin must be extensively processed before it
loses both its granular forming ability as well as its insolubility,
suggesting that granule formation in vivo correlates with insolubility
in vitro. Further, filaggrin retains its ability to bind keratins as it is
continually degraded to smaller peptides in the stratum corneum.
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